For some people, diabetes can be very hard to control, even with the standard glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. What’s the relationship between type 2 diabetes and hypercortisolism, and what do health care providers need to know about that relationship? To help answer those questions, host Aaron Lohr talks with two guests. , is a professor of medicine, assistant dean for clinical research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the section of endocrinology at Tulane University Medical Center in New Orleans. , is a professor of medicine and surgery at the Medical College of Wisconsin. Drs. Fonseca and Findling are authors of an article published in the journal looking at the CATALYST study: “Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.” This episode is made possible by support from Corcept Therapeutics Inc. Show notes are available at — for helpful links or to hear more podcast episodes, visit

In recent years, we have seen tremendous growth not just in the popularity of anti-obesity medications, but also in the medications themselves, how effective they are, how many there are. What exactly has changed during this rapid evolution? How safe and effective are these medications today? What challenges still exist in using them? To help answer these questions, host Aaron Lohr speaks with , professor of medicine, medical director of Vanderbilt Obesity Medicine, and founding program director of the Obesity Medicine Fellowship at Vanderbilt University Medical Center. Dr. Srivastava presented at the Endocrine Society’s Obesity Fellows Conference in September 2025. The title of her presentation was “Pharmacological Approaches to Treating and Understanding Complicated Obesity.” Listening to this episode can earn you 0.5 ABIM MOC points and 0.5 AMA PRA Category 1 credits. If you are interested in those points and credits, . You can find a link in this episode’s show notes. After that pre-test, listen to this episode , then take the post-test. This episode is made possible by educational grants from Lilly and Novo Nordisk. Show notes are available at — for helpful links or to hear more podcast episodes, visit

In the last five years, the field of artificial intelligence and robotics has taken off and has become a part of our everyday life, and it continues to grow and evolve. How are AI and robotics shaping the field of medicine? How is it improving the lives of doctors and patients? We used to ask, “What is the role of AI in medicine?” Are we getting closer to a time where we’ll be asking what the role is of humans? To help us answer these questions, host Aaron Lohr talks with . Dr. Heshmati has been a physician for 49 years and an endocrinologist for 45 years, with experience in clinical research and academia and in the pharmaceutical biotech industry. He founded Endocrinology Metabolism Consulting, based in Anthem, Ariz., and presented an abstract at ENDO 2025 titled, Show notes are available at — for helpful links or to hear more podcast episodes, visit

Technically known as glucagon-like peptide-1 receptor agonists, or GLP-1, these drugs have been around for years for treating diabetes. Now it seems most people think of GLP-1 drugs as medications to lose weight, and these medications are so popular that for a time, supply could not meet demand, leaving many to seek compounded GLP-1 medications, which were more accessible and affordable. However, compounded medications are not FDA-approved, and there are questions regarding their safety and efficacy. What do doctors and patients need to know when considering using compounded obesity medications? To help answer this, host Aaron Lohr talks with , an endocrinologist at NYU Langone Division of Endocrinology. Dr. Weintraub serves on the exam writing committee for the American Board of Obesity Medicine. Support for this episode was provided by Lilly. Show notes are available at — for helpful links or to hear more podcast episodes, visit

Bariatric surgery is a procedure used to manage obesity and obesity-related conditions. While studies have shown that bariatric surgery leads to significant weight loss, are there cases where it may be important to consider reversing the procedure? What would such cases look like? How effectively can bariatric surgery be reversed? To help explore those questions, host Aaron Lohr talks with , a second-year endocrine fellow at the University of Rochester Medical Center. She and colleagues presented an abstract at ENDO 2025 titled, “Going Backwards as a Means of Moving Forward: Severe Hypoglycemia After Bariatric Surgery.” Show notes are available at — for helpful links or to hear more podcast episodes, visit

In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with , assistant professor of medicine at Mayo Clinic Florida, and , a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at — for helpful links or to hear more podcast episodes, visit

In the United States, the Food and Drug Administration doesn’t regulate supplements for safety and efficacy, so manufacturers don’t have to disclose their ingredients. We can’t always know for certain what’s in supplements we buy over the counter. Host Aaron Lohr talks with , an endocrine specialist at Ochsner Lafayette General Medical Center in Louisiana. Dr. Pattipati presented a study at ENDO 2025 in San Francisco titled, “Beware of the Hidden Ingredients and Supplement Use in Your Patients With Elevated Testosterone.” The presentation describes a case where a patient unknowingly ingested an ingredient that had a significant endocrine impact. Show notes are available at — for helpful links or to hear more podcast episodes, visit

Recently the Endocrine Society held its 12th annual Type 1 Diabetes Fellows Series program, which combines comprehensive education on type 1 diabetes with career development opportunities to build knowledge, practical skills, and a lasting network of colleagues. For this episode, host Aaron Lohr talks with , medical director of the Diabetes Institute and director of the Clinical Research Center at the University of Florida. Dr. Schatz gave a talk at the fellows series program titled, “Immunotherapies for Type 1 Diabetes: Need for Early Detection and Screening.” This year’s fellows series program and this episode were made possible by the support of Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., and Vertex Pharmaceuticals Inc. Show notes are available at — for helpful links or to hear more podcast episodes, visit

In this episode, we cover type 1 diabetes and especially insulin delivery systems. Host Aaron Lohr talks with , from Northwestern University’s Feinberg School of Medicine and , director of education and training in diabetes technology at the Cleveland Clinic. This episode is certified for up to 0.5 AMA PRA Category 1 credits and ABIM MOC points. However, claiming those points requires taking a pre-episode test. Then you must listen to the episode on the Endocrine Society’s Center for Learning website, followed by a post-episode test and evaluation. Please check the show notes for the appropriate link. This episode is supported by educational grants by MannKind Corp. and Insulet Corp. Show notes are available at — for helpful links or to hear more podcast episodes, visit

Papillary thyroid cancer is the most common type of thyroid cancer, and yet in rare cases, this cancer may originate in locations other than the thyroid glands. In this episode, host Aaron Lohr talks about causes, prevalence, and treatment for papillary thyroid cancer and the rare phenomenon known as ectopic papillary thyroid cancer with , of University of Texas Health Science Center at Houston. Dr. Dhir and colleagues presented research at ENDO 2025 in San Francisco titled, “Where Is the Primary Papillary Thyroid Cancer?” Show notes are available at — for helpful links or to hear more podcast episodes, visit